• +1-646-491-9876
    • +91-20-67278686

    Search

    Fibrodysplasia Ossificans Progressiva Pipeline Review H1 2017

    Fibrodysplasia Ossificans Progressiva Pipeline Review H1 2017

    • Report Code ID: RW0001858652
    • Category Pharmaceuticals
    • No. of Pages 55
    • Publication Month Jun-17
    • Publisher Name Global Markets Direct
    Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Pipeline Review, H1 2017, provides an overview of the Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) (Musculoskeletal Disorders) pipeline landscape.

    Fibrodysplasia ossificans progressiva (FOP) is a disorder in which muscle tissue and connective tissue such as tendons and ligaments are gradually replaced by bone (ossified) , forming bone outside that constrains movement. Symptoms swellings in fibrous tissue, pain, fever, muscle ossification and restricted movement of joints. Treatment includes surgery and medications to help relieve symptoms of FOP, such as pain and inflammation.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) (Musculoskeletal Disorders) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 6 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.

    Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) (Musculoskeletal Disorders) .
    - The pipeline guide reviews pipeline therapeutics for Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) (Musculoskeletal Disorders)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) (Musculoskeletal Disorders) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Overview
    Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Pipeline by Universities/Institutes
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Companies Involved in Therapeutics Development
    AstraZeneca Plc
    Blueprint Medicines Corp
    Clementia Pharmaceuticals Inc
    Daiichi Sankyo Company Ltd
    La Jolla Pharmaceutical Company
    Oncodesign SA
    Pfizer Inc
    Regeneron Pharmaceuticals Inc
    Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Drug Profiles
    Antibody to Antagonize ALK2 for Fibrodysplasia Ossificans Progressiva - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    dipyridamole - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Drug for Fibrodysplasia Ossificans Progressiva - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    LJPC-6417 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    palovarotene - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    REGN-2477 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    REGN-2477 + trevogrumab - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    saracatinib difumarate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    sirolimus - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule 1 To Inhibit ALK2 for Fibrodysplasia Ossificans Progressiva - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule 2 To Inhibit ALK2 for Fibrodysplasia Ossificans Progressiva - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule to Inhibit Activin Receptor-Like Kinase 2 for fibrodysplasia ossificans progressiva - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule to Inhibit Activin Receptor-Like Kinase 2 for Fibrodysplasia Ossificans Progressiva - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule to Inhibit BMP for Cardiovascular, CNS, Oncology and Musculoskeletal Disorders - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Dormant Projects
    Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Product Development Milestones
    Featured News & Press Releases
    Jun 05, 2017: Clementia Pharmaceuticals to Host Symposium at the 8th International Conference on Children's Bone Health
    Mar 28, 2017: Phase 2 Part A Open Label Extension Trial of Palovarotene for Treatment of Patients with Fibrodysplasia Ossificans Progressiva Continues Positive Trends
    Oct 14, 2016: Clementia Announces Top-line Results from Phase 2 Trial of Palovarotene for Treatment of Patients with Fibrodysplasia Ossificans Progressiva
    Aug 08, 2016: Clementia Clinical Program: Opportunity for New Adult and Older Adolescent Subjects to Enroll in Palovarotene Study
    Jun 13, 2016: Clementia Clinical Program: Next Step in Clementia's Clinical Program for Fibrodysplasia Ossificans Progressiva (FOP)
    Apr 23, 2016: Clementia Pharmaceuticals Joins Global FOP Community in Recognizing Fibrodysplasia Ossificans Progressiva (FOP) Awareness Day
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) , H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Pipeline by AstraZeneca Plc, H1 2017
    Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Pipeline by Blueprint Medicines Corp, H1 2017
    Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Pipeline by Clementia Pharmaceuticals Inc, H1 2017
    Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Pipeline by Daiichi Sankyo Company Ltd, H1 2017
    Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Pipeline by La Jolla Pharmaceutical Company, H1 2017
    Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Pipeline by Oncodesign SA, H1 2017
    Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Pipeline by Pfizer Inc, H1 2017
    Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Pipeline by Regeneron Pharmaceuticals Inc, H1 2017
    Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Dormant Projects, H1 2017

    List of Figures

    Number of Products under Development for Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) , H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Number of Products by Targets, H1 2017
    Number of Products by Stage and Targets, H1 2017
    Number of Products by Top 10 Mechanism of Actions, H1 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Top 10 Molecule Types, H1 2017
    Number of Products by Stage and Top 10 Molecule Types, H1 2017
    AstraZeneca Plc
    Blueprint Medicines Corp
    Clementia Pharmaceuticals Inc
    Daiichi Sankyo Company Ltd
    La Jolla Pharmaceutical Company
    Oncodesign SA
    Pfizer Inc
    Regeneron Pharmaceuticals Inc

    Request for Sample

    Report Url https://www.reportsweb.com//fibrodysplasia-ossificans-progressiva-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url https://www.reportsweb.com//fibrodysplasia-ossificans-progressiva-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url https://www.reportsweb.com//fibrodysplasia-ossificans-progressiva-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments